Abstract LB-146: Phase I CD22 CAR T-cell trial updates
Nirali N. Shah(National Institutes of Health), Terry J. Fry(University of Colorado Anschutz Medical Campus), Constance M. Yuan(National Cancer Institute), Bonnie Yates(National Institutes of Health), Steve Highfill(National Institutes of Health), Jianjian Jin(National Institutes of Health Clinical Center), Crystal L. Mackall(Stanford University), Amanda K. Ombrello(National Human Genome Research Institute), Maryalice Stetler‐Stevenson(National Cancer Institute), Haneen Shalabi(Center for Cancer Research), Haiying Qin(National Institutes of Health), Minh Tran(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Sandhya R. Panch(University of Washington), David Stroncek(National Institutes of Health Clinical Center), Leah Hoffman(Medical College of Wisconsin)
Cited by 4
Related Papers
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
|Nature Communications|2016|435
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422